STOP Rabies: moving towards elimination STOP Rabies: moving towards elimination Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
Welcome to Innovation at Boehringer Ingelheim Welcome to Innovation at Boehringer Ingelheim Watch our video and find out more about innovation at Boehringer Ingelheim.
Grass Roots Grass Roots Grass Roots Innovation: Championing the Next Generation of Life-Science Innovators
Research-collaboration-Gubra-obesity-treatment Research-collaboration-Gubra-obesity-treatment Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
Future of Diabetes Future of Diabetes This video highlights the evolution of type 2 diabetes management
Ukraine Help: We fly, we bike, we accommodate Ukraine Help: We fly, we bike, we accommodate The solidarity for Ukraine from Boehringer Ingelheim employees is incredible. Equally impressive is their practical help.
Contact Us Contact Us Contact our partnering team to discuss your project and learn more about how we can work together.
Annual Results Press Conference Annual Results Press Conference Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Scleroderma Scleroderma Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs
EU approved Jardiance for type 2 diabetes in children EU approved Jardiance for type 2 diabetes in children Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
Two new claims for Nexgard range in EU and Australia Two new claims for Nexgard range in EU and Australia Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
Patient Safety & Pharmacovigilance at Boehringer Ingelheim Patient Safety & Pharmacovigilance at Boehringer Ingelheim Patients inspire us in our mission to lead the science that creates breakthrough therapies, so that our medicines transform patients’ lives.
vaxxitek® hvt + ibd + nd vaxxitek® hvt + ibd + nd Bursal Disease-Marek's disease-Newcastle disease vaccine, serotype 3, live Marek's disease vector; the vaccine includes a diluent
The liver and its vital connection to our overall health The liver and its vital connection to our overall health How health of the liver impacts our interconnected cardiovascular, renal, metabolic system and suffering and can have several comorbidities like obesity.
AI&Data Science Fellowship Tuebingen AI&Data Science Fellowship Tuebingen AI&Data Science Fellowship Tuebingen
Dessert and Drink Recipes Dessert and Drink Recipes Enjoy the selection of desserts and drinks from Taking Cancer on Through Flavour here.
Breakthrough introduction innovation pet parasiticides Breakthrough introduction innovation pet parasiticides In 2014, Boehringer introduced a new product, which became the first in a new class of isoxazoline products for flea and tick protection in dogs.
Making sustainable medicines through eco-design Making sustainable medicines through eco-design Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
Rainbow Pizza Video Rainbow Pizza Video Find out how this rainbow pizza from Taking Cancer on Through Flavour is made